Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

These symptoms can occur in people who are allergic to Anoro Ellipta. They can also occur in people who’ve had serious allergic reactions to milk proteins in the past. This is because milk protein ...

The U.S. Food and Drug Administration have approved GlaxoSmithKline’s Anoro™ Ellipta™, the company announced. The product is used to treat chronic obstructive ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...

A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro Ellipta is ...

BioWorld - Tuesday, November 21, 2023 See today's BioWorld Home » Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting Subscribe to BioWorld™ news services See subscription options To read the ...

FDA approves Tudorza Pressair for long-term COPD maintenance Data show no new safety signals, and an overall similar incidence of treatment-emergent adverse events ...

The FINANCIAL — GlaxoSmithKline plc (GSK) and Theravance, Inc. on September 27 announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an ...